

## CLAIMS

1-45. (Canceled)

46. (Currently Amended) A liquid pharmaceutical composition, comprising:  
a follicle stimulating hormone or a variant thereof,

m-cresol,

a diluent, and

at least one surfactant selected from the group consisting of poloxamer 188, poloxamer 217, poloxamer 237 and poloxamer 238~~PLURONIC F77, PLURONIC F87, PLURONIC F88 and PLURONIC F68~~.

47. (Previously Presented) The composition according to Claim 46, wherein the follicle stimulating hormone is present in an amount of from 150 IU/ml to 1200 IU/ml.

48. (Previously Presented) The composition according to Claim 46, wherein the follicle stimulating hormone is present in an amount of from 300 IU/ml to 900 IU/ml.

49. (Previously Presented) The composition according to Claim 46, wherein the follicle stimulating hormone is present in an amount of about 600 IU/ml.

50. (Currently Amended) The composition according to Claim 46, wherein the surfactant is poloxamer 188~~PLURONIC F68~~.

51. (Previously Presented) The composition according to Claim 46, wherein the follicle stimulating hormone is human follicle stimulating hormone.

52. (Previously Presented) The pharmaceutical composition according to Claim 46, wherein the follicle stimulating hormone is urinary human follicle stimulating hormone.

53. (Previously Presented) The composition according to Claim 46, wherein the follicle stimulating hormone is recombinant human follicle stimulating hormone.

54. (Cancelled)

55. (Cancelled)

56. (Currently Amended) The composition according to Claim ~~55~~46, comprising m-cresol in an amount of about 0.3% by mass based on the mass of the diluent.

57. (Previously Presented) The composition according to Claim 46, further comprising sucrose.

58. (Previously Presented) The composition according to Claim 46, further comprising methionine.

59. (Previously Presented) The composition according to Claim 46, further comprising a phosphate buffer, wherein the pH of the composition is from 6.0 to 8.0.

60. (Previously Presented) The composition according to Claim 46, further comprising a phosphate buffer, wherein the pH of the composition is about 7.0.

61. (Currently Amended) The composition according to Claim ~~54~~<sup>46</sup>, comprising the diluent, recombinant follicle stimulating hormone, poloxamer 188~~PLURONIC F68~~, sucrose, methionine, m-cresol, and an aqueous buffer, and wherein the pH of the composition is about 7.0.

62. (Currently Amended) The composition according to Claim 61, wherein the recombinant follicle stimulating hormone is present in an amount of about 600 IU/ml, the poloxamer 188~~PLURONIC F68~~ is present in an amount of about 0.1 mg/ml, the sucrose is present in an amount of about 60 mg/ml, the methionine is present in an amount of about 0.1 mg/ml, the m-cresol is present in an amount of about 3 mg/ml, and the phosphate buffer is present in an amount of about 10 mM in phosphate.

63. (Previously Presented) The composition according to Claim 46, wherein the diluent is water for injection.

64. (Previously Presented) The composition according to Claim 46, wherein the diluent is at least one of water and a mixture of water with a solvent miscible with water.

65.-71. (Cancelled)

72. (Currently Amended) A liquid pharmaceutical composition, comprising:

a follicle stimulating hormone or a variant thereof,

a luteinising hormone or a variant thereof,

at least one surfactant selected from the group consisting of poloxamer 188, poloxamer 217, poloxamer 237 and poloxamer 238~~PLURONIC F77, PLURONIC F87, PLURONIC F88 and PLURONIC F68~~, and

a diluent,

wherein the follicle stimulating hormone is human follicle stimulating hormone, the luteinising hormone is human luteinising hormone, or the follicle stimulating hormone is human follicle stimulating hormone and the luteinising hormone is human luteinising hormone.

73. (Currently Amended) A liquid pharmaceutical composition, comprising:

a follicle stimulating hormone or a variant thereof,

a luteinising hormone or a variant thereof,

at least one surfactant selected from the group consisting of poloxamer 188, poloxamer 217, poloxamer 237 and poloxamer 238~~PLURONIC F77, PLURONIC F87, PLURONIC F88 and PLURONIC F68~~, and

a diluent,

wherein the follicle stimulating hormone is urinary human follicle stimulating hormone, the luteinising hormone is urinary human luteinising hormone, or the follicle stimulating

hormone is urinary human follicle stimulating hormone and the luteinising hormone is urinary human luteinising hormone.

74. (Currently Amended) A liquid pharmaceutical composition, comprising:

a follicle stimulating hormone or a variant thereof,

a luteinising hormone or a variant thereof,

at least one surfactant selected from the group consisting of poloxamer 188, poloxamer 217, poloxamer 237 and poloxamer 238~~PLURONIC F77, PLURONIC F87, PLURONIC F88 and PLURONIC F68~~, and

a diluent,

wherein the follicle stimulating hormone is recombinant human follicle stimulating hormone, the luteinising hormone is recombinant human luteinising hormone, or the follicle stimulating hormone is recombinant human follicle stimulating hormone and the luteinising hormone is recombinant human luteinising hormone.

75. (Previously Presented) The composition according to Claim 72, wherein the follicle stimulating hormone and the luteinising hormone are present in a ratio of from 6:1 to 1:6.

76. (Previously Presented) The composition according to Claim 72, wherein the follicle stimulating hormone and the luteinising hormone are present in a ratio of from 4:1 to 1:2.

77. (Previously Presented) The composition according to Claim 72, wherein the follicle stimulating hormone and the luteinising hormone are present in a ratio of from 3:1 to 1:1.

78. (Previously Presented) The composition according to Claim 72, wherein the follicle stimulating hormone and the luteinising hormone are present in a ratio of from 2:1 to 1:1.

79. (Previously Presented) The composition according to Claim 72, further comprising phenol .

80. (Previously Presented) The composition according to Claim 72, further comprising m-cresol.

81. (Cancelled)

82. (Previously Presented) The composition according to Claim 72, further comprising sucrose.

83. (Previously Presented) The composition according to Claim 72, further comprising methionine.

84. (Previously Presented) The composition according to Claim 72, further comprising a phosphate buffer, wherein the pH of the composition is from 6.0 to 8.0.

85. (Previously Presented) The composition according to Claim 72, further comprising a phosphate buffer, wherein the pH of the composition is about 7.0.

86. (Currently Amended) The composition according to Claim 72, comprising the diluent, recombinant follicle stimulating hormone, poloxamer 188~~PLURONIC F68~~, sucrose, methionine, phenol, and an aqueous buffer, wherein the pH of the composition is about 7.0.

87. (Currently Amended) The composition according to Claim 86, wherein the recombinant follicle stimulating hormone is present in an amount of about 600 IU/ml, the poloxamer 188~~PLURONIC F68~~ is present in an amount of about 0.1 mg/ml, the sucrose is present in an amount of about 60 mg/ml, the methionine is present in an amount of about 0.1 mg/ml, the phenol is present in an amount of about 3 mg/ml, and the buffer is a phosphate buffer present in an amount of about 10 mM in phosphate.

88. (Previously Presented) The composition according to Claim 72, wherein the diluent is water for injection.

89. (Previously Presented) The composition according to Claim 72, wherein the diluent is at least one of water and a mixture of water and a solvent miscible with water.

90-188. (Cancelled)

189. (Previously Presented) The composition according to Claim 72, wherein the follicle stimulating hormone is present in an amount of from 150 IU/ml to 1200 IU/ml.

190. (Previously Presented) The composition according to Claim 72, wherein the follicle stimulating hormone is present in an amount of from 300 IU/ml to 900 IU/ml.

191. (Previously Presented) The composition according to Claim 72, wherein the follicle stimulating hormone is present in an amount of about 600 IU/ml.

192. (Previously Presented) The composition according to Claim 72, wherein the luteinising hormone is present in an amount of from 150 IU/ml to 1200 IU/ml.

193. (Previously Presented) The composition according to Claim 72, wherein the luteinising hormone is present in an amount of from 300 IU/ml to 750 IU/ml.

194. (Currently Amended) The composition according to Claim 72, wherein the surfactant is poloxamer 188~~PLURONIC F68~~.

195. (Previously Presented) The composition according to Claim 86, wherein the luteinising hormone is recombinant luteinising hormone.

196. (Previously Presented) The composition according to Claim 195, wherein the follicle stimulating hormone and the luteinising hormone are present in a ratio of from 2:1.

197. (Previously Presented) The composition according to Claim 196, wherein the buffer is a phosphate buffer.



198. (New) A liquid pharmaceutical composition, comprising:  
a follicle stimulating hormone or a variant thereof,  
phenol,  
a diluent, and  
at least one surfactant selected from the group consisting of poloxamer 188, poloxamer 217, poloxamer 237 and poloxamer 238.

199. (New) The composition according to Claim 198, wherein the follicle stimulating hormone is present in an amount of from 150 IU/ml to 1200 IU/ml.

200. (New) The composition according to Claim 198, wherein the follicle stimulating hormone is present in an amount of from 300 IU/ml to 900 IU/ml.

201. (New) The composition according to Claim 198, wherein the follicle stimulating hormone is present in an amount of about 600 IU/ml.

202. (New) The composition according to Claim 198, wherein the surfactant is poloxamer 188.

203. (New) The composition according to Claim 198, wherein the follicle stimulating hormone is human follicle stimulating hormone.

204. (New) The pharmaceutical composition according to Claim 198, wherein the follicle stimulating hormone is urinary human follicle stimulating hormone.

205. (New) The composition according to Claim 198, wherein the follicle stimulating hormone is recombinant human follicle stimulating hormone.

206. (New) The composition according to Claim 198, further comprising sucrose.

207. (New) The composition according to Claim 198, further comprising methionine.

208. (New) The composition according to Claim 198, further comprising a phosphate buffer, wherein the pH of the composition is from 6.0 to 8.0.

209. (New) The composition according to Claim 198, further comprising a phosphate buffer, wherein the pH of the composition is about 7.0.

210. (New) The composition according to Claim 198, wherein the diluent is water for injection.

211. (New) The composition according to Claim 198, wherein the diluent is at least one of water and a mixture of water with a solvent miscible with water.